Daehan New Pharm Co. Ltd (054670) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.43 Billion ≈ $3.00 Million USD) by net assets (₩129.44 Billion ≈ $87.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Daehan New Pharm Co. Ltd (054670) market capitalisation for the company's overall valuation and market capitalisation.

Daehan New Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Daehan New Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Daehan New Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Daehan New Pharm Co. Ltd to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Microtips Technology TWO:3285	-0.027x
Nimbus Group AB ST:BOAT	0.150x
Bridgford Foods Corporation NASDAQ:BRID	-0.020x
Harmoney Corp Ltd AU:HMY	0.514x
Top Win International Limited NASDAQ:SORA	-0.540x
Zimmite Taiwan Ltd TWO:8435	0.059x
Greenland Energy Company Common Stock NASDAQ:GLND	-0.031x
Generic Sweden publ AB ST:GENI	0.190x

Annual Cash Flow Conversion Efficiency for Daehan New Pharm Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Daehan New Pharm Co. Ltd from 2014 to 2024. View current stock price of Daehan New Pharm Co. Ltd for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩125.44 Billion ≈ $85.01 Million	₩18.95 Billion ≈ $12.84 Million	0.151x	+31.44%
2023-12-31	₩109.36 Billion ≈ $74.11 Million	₩12.57 Billion ≈ $8.52 Million	0.115x	-16.99%
2022-12-31	₩102.96 Billion ≈ $69.77 Million	₩14.25 Billion ≈ $9.66 Million	0.138x	-31.16%
2021-12-31	₩82.47 Billion ≈ $55.89 Million	₩16.58 Billion ≈ $11.24 Million	0.201x	-15.19%
2020-12-31	₩57.13 Billion ≈ $38.72 Million	₩13.55 Billion ≈ $9.18 Million	0.237x	-36.75%
2019-12-31	₩61.07 Billion ≈ $41.38 Million	₩22.89 Billion ≈ $15.51 Million	0.375x	-21.12%
2018-12-31	₩43.08 Billion ≈ $29.19 Million	₩20.47 Billion ≈ $13.87 Million	0.475x	+1113.94%
2017-12-31	₩51.72 Billion ≈ $35.05 Million	₩-2.42 Billion ≈ $-1.64 Million	-0.047x	-138.14%
2016-12-31	₩71.20 Billion ≈ $48.25 Million	₩8.75 Billion ≈ $5.93 Million	0.123x	+21.58%
2015-12-31	₩77.20 Billion ≈ $52.32 Million	₩7.80 Billion ≈ $5.29 Million	0.101x	-25.43%
2014-12-31	₩73.89 Billion ≈ $50.07 Million	₩10.02 Billion ≈ $6.79 Million	0.136x	--

About Daehan New Pharm Co. Ltd

KQ:054670 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$52.98 Million

₩78.18 Billion KRW

Market Cap Rank

#21781 Global

#1307 in Korea

Share Price

₩5570.00

Change (1 day)

+0.00%

52-Week Range

₩5090.00 - ₩7510.00

All Time High

₩21012.38